Memantine for dementia
... Sastre A, Minakaran N. Memantine for dementia. ... of efficacy of memantine for dementia ... randomized trials of memantine in people with dementia. ...
Information about Dementia at memantine.com
Memantine.com | Dementia: Here you get information about forms of diseases, drugs, therapies, care and latest research results.
Information about Dementia Medication at memantine.com
Memantine.com | Dementia Medication: Here you get information about forms of diseases, drugs, therapies, care and latest research results.
Memantine - Wikipedia, the free encyclopedia
Memantine is also being tested for opioid dependence, systemic lupus ... Memantine for dementia". Cochrane Database Syst Rev (3): CD003154. ...
memantine (Namenda) - drug class, medical uses, medication side effects ...
Specifies the medication memantine (Namenda), a drug used for the treatment of moderate to severe dementia of the Alzheimer's type.
Memantine for dementia.
Memantine for dementia. Areosa SA, Sherriff F. ... of memantine for people with Alzheimer's disease, or vascular or mixed dementia. ...
Memantine for dementia.
Memantine for dementia. Areosa SA, Sherriff F, McShane R. ... placebo-controlled, randomized trials of memantine in people with dementia. ...
Treatments for Dementia & Memantine - DementiaGuide.com - DementiaGuide.com
Memantine goes by several trade names including Ebixa, Nameda and Axura. ... Treatments for Dementia. Cholinesterase Inhibitors. Memantine. Neuroleptics ...
Memantine for dementia(Cochrane Review)
Abstract of a systematic review of the effects of health care prepared by ... Memantine for dementia (Cochrane Review) Areosa Sastre A, Sherriff F. ABSTRACT ...
Memantine
Memantine is used for patients who already have moderate to ... in dementia with Lewy bodies: worsening with memantine. ... Memantine for dementia ...
|
Memantine for dementia in people with Down syndrome - NeLM
Memantine for dementia in people with Down syndrome
Alzheimer's dementia (AD) is the most common form of dementia in people with Down Syndrome (DS). There is an understanding that an increase in L-glutamate contributes to the pathogenesis of cerebral ischemias and AD. Memantine acts as an antagonist of N-methyl-D-aspartate (NMDA) type receptors, which is thought to reduce abnormal activation of glutamate neurotransmission. It binds with a low affinity to the NMDA receptor and so should not prevent learning and the formation of memory. Memantine can improve cognitive function and slow the decline of AD in the general population over time, and is the subject of this review. It is important to note that people with DS tend to present with AD at a much younger age than the normal population as well as having subtle differences in physiology (e.g.